Echo Therapeutics (ECTE) Reports In-Line Q2 Loss of 6c/Share

Echo Therapeutics (NASDAQ: ECTE) reported Q2 loss of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $121.46 thousand versus the consensus estimate of $100 thousand.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Prenetics Global (PRE) Tops Q2 EPS by 18c
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance